308 related articles for article (PubMed ID: 20410545)
1. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Elefante A; Czuczman MS
Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
Hoy SM
Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Ujjani C; Cheson BD
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Garnock-Jones KP
Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477
[TBL] [Abstract][Full Text] [Related]
7. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Vidal L; Gafter-Gvili A; Gurion R; Raanani P; Dreyling M; Shpilberg O
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009045. PubMed ID: 22972131
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine: rebirth of an old drug.
Cheson BD; Rummel MJ
J Clin Oncol; 2009 Mar; 27(9):1492-501. PubMed ID: 19224851
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine therapy in chronic lymphocytic leukemia.
Masiello D; Tulpule A
Expert Opin Pharmacother; 2009 Jul; 10(10):1687-98. PubMed ID: 19527193
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.
Plosker GL; Carter NJ
Drugs; 2008; 68(18):2645-60. PubMed ID: 19093705
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine: new perspective for an old drug in lymphoproliferative disorders.
Montillo M; Ricci F; Tedeschi A; Vismara E; Morra E
Expert Rev Hematol; 2010 Apr; 3(2):131-48. PubMed ID: 21083456
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine (Treanda) for CLL and NHL.
Med Lett Drugs Ther; 2008 Nov; 50(1299):91-2. PubMed ID: 19008789
[No Abstract] [Full Text] [Related]
16. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
Glode AE; Jarkowski A
Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
[TBL] [Abstract][Full Text] [Related]
19. BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
Bogeljić Patekar M; Milunović V; Mišura Jakobac K; Perica D; Mandac Rogulj I; Kursar M; Planinc-Peraica A; Ostojić Kolonić S
Acta Clin Croat; 2018 Sep; 57(3):542-553. PubMed ID: 31168188
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Rummel MJ; Mitrou PS; Hoelzer D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
